{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T10:19:43Z","timestamp":1698661183582},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,23]]},"DOI":"10.1097\/qad.0000000000000819","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T10:00:59Z","timestamp":1437645659000},"page":"2155-2159","source":"Crossref","is-referenced-by-count":4,"title":["Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice"],"prefix":"10.1097","volume":"29","author":[{"given":"Claudia","family":"Palladino","sequence":"first","affiliation":[]},{"given":"Mar\u00eda Luisa Navarro","family":"G\u00f3mez","sequence":"additional","affiliation":[]},{"given":"Pere","family":"Soler-Palac\u00edn","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda Isabel","family":"Gonz\u00e1lez-Tom\u00e9","sequence":"additional","affiliation":[]},{"given":"Santiago J.","family":"De Ory","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda","family":"Espiau","sequence":"additional","affiliation":[]},{"given":"Santiago P\u00e9rez","family":"Hoyos","sequence":"additional","affiliation":[]},{"given":"Juan Antonio","family":"Le\u00f3n-Leal","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda","family":"M\u00e9ndez","sequence":"additional","affiliation":[]},{"given":"David","family":"Moreno-P\u00e9rez","sequence":"additional","affiliation":[]},{"given":"Claudia Fortuny","family":"Guasch","sequence":"additional","affiliation":[]},{"given":"Antoni Mur","family":"Sierra","sequence":"additional","affiliation":[]},{"given":"Itziar Pocheville","family":"Guruceta","sequence":"additional","affiliation":[]},{"given":"Santiago Moreno","family":"Guill\u00e9n","sequence":"additional","affiliation":[]},{"given":"Ver\u00f3nica","family":"Briz","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-15-20210130","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/QAD.0000000000000316","article-title":"Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis.","volume":"28","author":"Kim","year":"2014","journal-title":"AIDS"},{"key":"R2-15-20210130","first-page":"14","article-title":"A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth.","volume":"17","author":"Reisner","year":"2009","journal-title":"Top HIV Med"},{"key":"R3-15-20210130","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity.","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-15-20210130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3182a7a97a","article-title":"Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.","volume":"65","author":"Gulick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-15-20210130","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.","volume":"359","author":"Fatkenheuer","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-15-20210130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0000000000000131","article-title":"Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.","volume":"28","author":"Cooper","year":"2014","journal-title":"AIDS"},{"key":"R8-15-20210130","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4 T-cell recovery: a randomized trial.","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"R9-15-20210130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jis376","article-title":"A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4() T-cell recovery despite sustained virologic suppression: ACTG A5256.","volume":"206","author":"Wilkin","year":"2012","journal-title":"J Infect Dis"},{"key":"R10-15-20210130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"R11-15-20210130","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/QAD.0b013e328361d0e1","article-title":"Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.","volume":"27","author":"Gutierrez","year":"2013","journal-title":"AIDS"},{"key":"R12-15-20210130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1310\/hct1302-83","article-title":"Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.","volume":"13","author":"Lazzarin","year":"2012","journal-title":"HIV Clin Trials"},{"key":"R13-15-20210130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/11590700-000000000-00000","article-title":"Clinical utility of maraviroc.","volume":"31","author":"Parra","year":"2011","journal-title":"Clin Drug Investig"},{"key":"R18-15-20210130","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1128\/JCM.00953-10","article-title":"TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.","volume":"48","author":"Gonzalez-Serna","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R19-15-20210130","first-page":"94","article-title":"An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies.","volume":"3","author":"Reeves","year":"2009","journal-title":"J Viral Entry"},{"key":"R20-15-20210130","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1371","article-title":"Bioinformatics prediction of HIV coreceptor usage.","volume":"25","author":"Lengauer","year":"2007","journal-title":"Nat Biotechnol"},{"key":"R24-15-20210130","first-page":"642","article-title":"2014 Update of the Drug Resistance Mutations in HIV-1.","volume":"22","author":"Wensing","year":"2014","journal-title":"Topics Antiviral Med"},{"key":"R25-15-20210130","first-page":"1048","article-title":"High prevalence of X4DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.","volume":"31","author":"Briz","year":"2012","journal-title":"Pediatr Infect Dis J"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000000819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:13:14Z","timestamp":1620969194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201510230-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000000819","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10,23]]}}}